HighVista Strategies’s Travere Therapeutics TVTX Stock Holding History

HighVista Strategies’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.08M	Buy	+36,325	New	+$1.09M	0.3%	107
2024 Q4	–	Sell	-147,233	Closed	-$2.06M	–	166
2024 Q3	$2.06M	Sell	147,233 -72,183	-33%	-$752K	0.71%	43
2024 Q2	$1.8M	Hold	219,416	–	–	0.66%	47
2024 Q1	$1.69M	Hold	219,416	–	–	0.6%	57
2023 Q4	$1.97M	Buy	219,416 +97,016	+79%	+$706K	0.72%	46
2023 Q3	$1.09M	Buy	122,400 +97,003	+382%	+$1.37M	0.51%	55
2023 Q2	$390K	Sell	25,397 -96,437	-79%	-$1.75M	0.18%	127
2023 Q1	$2.74M	Hold	121,834	–	–	2.23%	11
2022 Q4	$2.56M	Buy	121,834 +11,136	+10%	+$236K	1.52%	20
2022 Q3	$2.73M	Buy	110,698 +6,548	+6%	+$169K	1.56%	23
2022 Q2	$2.52M	Buy	104,150 +71,649	+220%	+$1.8M	1.52%	21
2022 Q1	$838K	Sell	32,501 -21,602	-40%	-$574K	0.53%	54
2021 Q4	$1.68M	Sell	54,103 -2,591	-5%	-$73K	1.34%	17
2021 Q3	$1.38M	Buy	56,694 +3,196	+6%	+$58.7K	0.91%	24
2021 Q2	$781K	Buy	53,498 +28,876	+117%	+$570K	0.55%	54
2021 Q1	$615K	Buy	+24,622	New	+$680K	0.46%	55

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HighVista Strategies's TVTX Position: Q1 2026 in Review

HighVista Strategies opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 36,325 shares worth $1.08M. The stake represents 0.3% of the portfolio and ranks #107 among its holdings. This is a return to the name: HighVista Strategies previously reported a position in TVTX as recently as Q3 2024.

HighVista Strategies first reported a position in TVTX in Q1 2021 and has held it in 16 quarters since. The position peaked at $2.74M in Q1 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

HighVista Strategies held 36,325 shares of Travere Therapeutics worth $1.08M as of Q1 2026.
Travere Therapeutics was a new HighVista Strategies position in Q1 2026.
Travere Therapeutics made up 0.3% of HighVista Strategies's portfolio in Q1 2026, its #107 holding.
HighVista Strategies first reported a position in Travere Therapeutics in Q1 2021 and has held it in 16 quarters since.
HighVista Strategies's Travere Therapeutics position peaked at $2.74M in Q1 2023.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.